CK Nutraceuticals partners with Kunpoong to distribute chitosan oligosaccharide

44d7d4b0-0873-4616-99a0-0f68e30897ffarticleimage.jpg

28 Sep 2017 --- South Korea’s Kunpoong Bio Co. Ltd., a global operator in the chitosan oligosaccharide market, has appointed Toronto-based CK Nutraceuticals (CK) as its exclusive North America sales, marketing and distribution partner for its Go2Ka1 ingredient (branded as KitoMax in North America).

CK focuses on supplying functional and nutritional ingredients for the functional food, beverage, dietary supplement and sports nutrition markets in North America. Kunpoong, based in Seoul, produces and supplies chitosan oligosaccharide for use in pharmaceutical, food and agricultural applications.

Under the terms of the multi-year agreement, CK is to promote advanced glucose management nutraceutical KitoMax to its extensive base of dietary supplement clients in both the US and Canada.

Solution backed by science
“We see increasing consumer and industry interest in the blood glucose management category, and we believe that KitoMax is a safe, effective and scientifically-proven solution in this important health category,” Michael Chernyak, President of CK Nutraceuticals, tells NutritionInsight.

KitoMax is a patent-pending chitosan-oligosaccharide produced using advanced enzymatic technology, the CK press release states. It has a well-defined mechanism of action, and is supported by three published clinical studies that demonstrate meaningful blood glucose control benefits.

CK adds that the applications of KitoMax include capsules, tablets, nutrition bars, stick packs, powdered drink mixes, gummies and more.

Several compelling structure/function claims have been defined for KitoMax in the US, and in Canada it has received a license from Health Canada with the approved claims “Helps to support healthy glucose metabolism,” “Helps to maintain healthy glucose metabolism,” “Helps maintain healthy blood sugar levels” and “Helps support healthy blood sugar levels.”

Chernyak also points to three published clinical trials that demonstrate: immediate effect on post-prandial blood glucose levels post-meal (sugar and bread/starch); and long-term administration effect, especially in reducing HbA1c and waist circumference.

“What is also important to note is that the long-term clinical trial was performed in a pre-diabetic population that was receiving no other medical intervention (to our knowledge, this is the only report of a natural product reducing HbA1c in pre-diabetic population),” Chernyak adds.

There is a team of scientists who collectively have more than 100 publications in the field of Type 2 diabetes prevention on board, Chernyak points out.

“We are thrilled to collaborate with Kunpoong Bio on this terrific ingredient, which we believe is very timely,” says Chernyak. “Our mission is to supply our North American clients with superior raw materials that are backed by scientific research of the very highest quality, and KitoMax certainly fits the bill.”

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

HMO expansion: Jennewein Biotechnologie to strengthen portfolio with Arthus Mineralsprings facility buy

09 0ct 2018 --- Jennewein Biotechnologie is to expand its production of human milk oligosaccharides (HMO) from its current portfolio of two products to include five more. The expansion is facilitated through the company's acquisition of the former facilities of Arthus Mineralsprings in Bad Hönningen, Germany. Jennewein plans to build a new integrated fermentation and recovery plant for the production of HMOs.

Health & Nutrition News

Mundipharma to globally commercialize kiwifruit gut health supplement

07 Sep 2018 --- Pharmaceutical company Mundipharma has closed an asset purchase agreement with Vital Food Processors Limited,  an agricultural science company founded in New Zealand, for the global rights to commercialize Zyactinase – a clinically-proven gastrointestinal consumer health product. Zyactinase is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements. 

Health & Nutrition News

Fazer Mills launches “first convenient” enzyme solution for low-FODMAP baking

06 Sep 2018 --- Finnish miller and oat producer Fazer Mills has developed an enzyme-based solution that the company says provides a low-FODMAP feature for wheat and rye baking. The company touts the patented LOFO enzyme, incorporated into Fazer LOFO improver, as the world’s first convenient low-FODMAP baking solution. 

Health & Nutrition News

GOS holds dietary fiber potential: FrieslandCampina eyes new applications

13 Aug 2018 --- FrieslandCampina is targeting the dietary fiber opportunity for its Galacto-Oligosaccharides (GOS). The move comes in response to the recent FDA green light on specific dietary fibers which presents new market opportunities and application areas. “There is a lot of interest in clean, green and label-friendly ingredients and fiber is one that they are looking for, but in good tasting applications. This really means a lot more flexibility for formulators to offer something that has both prebiotic and fiber benefits,” Sarah Staley of FrieslandCampina tells NutritionInsight on the topic of GOS as a trending prebiotic fiber.

Health & Nutrition News

Australia’s Manildra Group launches low FODMAP flour

03 Aug 2018 --- Australian flour miller Manildra Group has launched a low FODMAP flour range, touted as being “the world’s first.” Tested by government-registered Australian certifier FODMAP Friendly with DTS laboratories, Lo-Fo Pantry Plain Flour has been approved for millions of Australians who suffer IBS-like abdominal symptoms but get no relief from a gluten-free diet. 

More Articles
URL : http://www.nutritioninsight.com:80/news/ck-nutraceuticals-partners-with-kunpoong-to-distribute-chitosan-oligosaccharide.html